Opinions & Features

For years, Celgene presided as de facto master of ceremonies at the J.P. Morgan Healthcare Conference by being the opening act of this premier life sciences event.

During last Thursday’s Forbes Healthcare Summit, the final panel was entitled “Can We Cure Cancer,” and presented a unique view of the future of cancer therapy. Unlike many cancer panel discussions, the panelists were refreshingly[...]

When the person who successfully upended the broadcast radio industry model with the launch of Sirius XM satellite radio and then successfully challenged the drug development model to create new drugs for rare diseases now[...]

Yesterday Corium International Inc. announced its shares were being purchased at a 50% premium to their closing price along with a Contingent Value Right by a private investment firm focused on healthcare and life sciences,[...]

Walking around the convention floor at BIO was a remarkable experience this week in Boston. Not only were there an endless number of human health companies present, there were also animal health companies.

Celgene’s acquisition of Juno is probably the most anticipated acquisition of the last 24 months. Having previously made a $1 billion investment a little over two years ago, Celgene completed its courtship of the company[...]

In today’s social and political climate, public opinion and public action can galvanize and turn on an issue in an instant.

In a joint press release Sunday night, CVS Health and Aetna stated that one of the goals behind the nation's largest pharmacy chain acquiring one of its largest health insurers is to save the healthcare[...]

It's now a foregone conclusion that Amazon.com, Inc. will enter the healthcare sector.

After years of anticipation, the world learned on Monday that Gilead Sciences Inc. will acquire Kite Pharma Inc. for almost $12 billion in cash.